Back

SK Biopharmaceuticals’ Cenobamate wins Japan approval, completing Northeast Asia rollout

Verifying
  • SK Biopharmaceuticals said Ono Pharmaceutical secured Japan approval for Cenobamate.
  • Japan has approximately 1 million epilepsy patients, with roughly 30% inadequately controlled.
  • Cenobamate previously gained South Korean approval in November and Chinese approval in December.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.